Skip to main content
. 2017 Mar 22;19(6):845–852. doi: 10.1093/neuonc/nox020

Table 3.

Patients with reported responses

Mibefradil Dose Level (mg per day) Age and Gender Pathology Review Assessment by Site Investigator Central Review
100 67 F GBM Partial response Stable disease
200 50 M GBM Partial response Stable disease
200 43 F GBM Partial response Partial response
300 33 M GBM Complete response Complete response
350 (MTD) 71 M GBM Complete response Stable disease
350 (MTD) 43 M GBM Complete response Stable disease

GBM = glioblastoma.